Cargando…
Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
Baricitinib (Olumiant(®)) is an oral small molecule inhibitor of Janus kinase (JAK)1 and JAK2, which have been implicated in the pathogenesis of atopic dermatitis (AD). In phase III studies in adults with moderate to severe AD who were inadequately controlled with topical corticosteroids (TCS) or sy...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061224/ https://www.ncbi.nlm.nih.gov/pubmed/35503162 http://dx.doi.org/10.1007/s40257-022-00684-1 |